vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
Xometry, Inc. is the larger business by last-quarter revenue ($192.4M vs $164.7M, roughly 1.2× PTC THERAPEUTICS, INC.). Xometry, Inc. runs the higher net margin — -4.5% vs -82.0%, a 77.5% gap on every dollar of revenue. On growth, Xometry, Inc. posted the faster year-over-year revenue change (29.5% vs -22.7%). Xometry, Inc. produced more free cash flow last quarter ($-5.9M vs $-36.6M). Over the past eight quarters, Xometry, Inc.'s revenue compounded faster (25.2% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
PTCT vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $192.4M |
| Net Profit | $-135.0M | $-8.6M |
| Gross Margin | — | 39.1% |
| Operating Margin | -43.3% | -4.6% |
| Net Margin | -82.0% | -4.5% |
| Revenue YoY | -22.7% | 29.5% |
| Net Profit YoY | -104.8% | 12.7% |
| EPS (diluted) | $-1.63 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $164.7M | $192.4M | ||
| Q3 25 | $211.0M | $180.7M | ||
| Q2 25 | $178.9M | $162.5M | ||
| Q1 25 | $1.2B | $151.0M | ||
| Q4 24 | $213.2M | $148.5M | ||
| Q3 24 | $196.8M | $141.7M | ||
| Q2 24 | $186.7M | $132.6M | ||
| Q1 24 | $210.1M | $122.7M |
| Q4 25 | $-135.0M | $-8.6M | ||
| Q3 25 | $15.9M | $-11.6M | ||
| Q2 25 | $-64.8M | $-26.4M | ||
| Q1 25 | $866.6M | $-15.1M | ||
| Q4 24 | $-65.9M | $-9.9M | ||
| Q3 24 | $-106.7M | $-10.2M | ||
| Q2 24 | $-99.2M | $-13.7M | ||
| Q1 24 | $-91.6M | $-16.6M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | -43.3% | -4.6% | ||
| Q3 25 | 1.4% | -6.1% | ||
| Q2 25 | -19.5% | -6.3% | ||
| Q1 25 | 82.5% | -10.2% | ||
| Q4 24 | -76.2% | -7.8% | ||
| Q3 24 | -27.7% | -8.1% | ||
| Q2 24 | -21.5% | -11.5% | ||
| Q1 24 | -21.6% | -14.6% |
| Q4 25 | -82.0% | -4.5% | ||
| Q3 25 | 7.5% | -6.4% | ||
| Q2 25 | -36.3% | -16.3% | ||
| Q1 25 | 73.7% | -10.0% | ||
| Q4 24 | -30.9% | -6.7% | ||
| Q3 24 | -54.2% | -7.2% | ||
| Q2 24 | -53.1% | -10.3% | ||
| Q1 24 | -43.6% | -13.5% |
| Q4 25 | $-1.63 | — | ||
| Q3 25 | $0.20 | — | ||
| Q2 25 | $-0.83 | — | ||
| Q1 25 | $10.04 | — | ||
| Q4 24 | $-0.85 | — | ||
| Q3 24 | $-1.39 | — | ||
| Q2 24 | $-1.29 | — | ||
| Q1 24 | $-1.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-205.3M | $275.6M |
| Total Assets | $2.9B | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9B | $219.1M | ||
| Q3 25 | $1.7B | $224.5M | ||
| Q2 25 | $2.0B | $225.8M | ||
| Q1 25 | $2.0B | $231.4M | ||
| Q4 24 | $1.1B | $239.8M | ||
| Q3 24 | $1.0B | $234.0M | ||
| Q2 24 | $1.1B | $240.9M | ||
| Q1 24 | $884.8M | $253.8M |
| Q4 25 | $-205.3M | $275.6M | ||
| Q3 25 | $-155.8M | $272.0M | ||
| Q2 25 | $-206.5M | $270.4M | ||
| Q1 25 | $-185.8M | $309.9M | ||
| Q4 24 | $-1.1B | $314.5M | ||
| Q3 24 | $-1.1B | $315.2M | ||
| Q2 24 | $-980.2M | $315.8M | ||
| Q1 24 | $-893.9M | $320.4M |
| Q4 25 | $2.9B | $703.7M | ||
| Q3 25 | $2.6B | $698.9M | ||
| Q2 25 | $2.6B | $687.0M | ||
| Q1 25 | $2.7B | $690.1M | ||
| Q4 24 | $1.7B | $680.1M | ||
| Q3 24 | $1.8B | $678.2M | ||
| Q2 24 | $1.9B | $678.6M | ||
| Q1 24 | $1.8B | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $4.4M |
| Free Cash FlowOCF − Capex | $-36.6M | $-5.9M |
| FCF MarginFCF / Revenue | -22.3% | -3.0% |
| Capex IntensityCapex / Revenue | 1.4% | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.3M | $4.4M | ||
| Q3 25 | $-66.3M | $5.8M | ||
| Q2 25 | $-58.3M | $-427.0K | ||
| Q1 25 | $870.1M | $-3.7M | ||
| Q4 24 | $-30.0M | $9.1M | ||
| Q3 24 | $-77.0M | $-3.6M | ||
| Q2 24 | $-71.5M | $-9.1M | ||
| Q1 24 | $70.8M | $-11.7M |
| Q4 25 | $-36.6M | $-5.9M | ||
| Q3 25 | $-69.7M | $-1.7M | ||
| Q2 25 | $-59.6M | $-7.4M | ||
| Q1 25 | $868.4M | $-9.2M | ||
| Q4 24 | $-33.8M | $4.5M | ||
| Q3 24 | $-77.5M | $-8.4M | ||
| Q2 24 | $-78.8M | $-13.5M | ||
| Q1 24 | $61.2M | $-16.1M |
| Q4 25 | -22.3% | -3.0% | ||
| Q3 25 | -33.1% | -0.9% | ||
| Q2 25 | -33.3% | -4.5% | ||
| Q1 25 | 73.8% | -6.1% | ||
| Q4 24 | -15.8% | 3.1% | ||
| Q3 24 | -39.4% | -6.0% | ||
| Q2 24 | -42.2% | -10.2% | ||
| Q1 24 | 29.1% | -13.1% |
| Q4 25 | 1.4% | 5.3% | ||
| Q3 25 | 1.6% | 4.1% | ||
| Q2 25 | 0.7% | 4.3% | ||
| Q1 25 | 0.1% | 3.6% | ||
| Q4 24 | 1.8% | 3.1% | ||
| Q3 24 | 0.3% | 3.4% | ||
| Q2 24 | 4.0% | 3.3% | ||
| Q1 24 | 4.6% | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | -4.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTCT
Segment breakdown not available.
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
